Inferra AI / Company / MDLN
Medline
MDLN · Health Care
Last earnings Aug 5, 2026
Key results
Net incomequarter
25.8%
First quarter 2026 net income decreased 25.8% to $239 million, compared to $322 million in the first quarter 2025, primarily driven by higher costs of goods sold including the impact of tariffs, higher operating expenses to support new customer growth and an employee bonus related to the Company s IPO.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
Adjusted EPSquarter
$0.16
Diluted earnings per share and Adjusted Diluted EPS were $0.16 and $0.33, respectively.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
Free cash flowquarter
$316 million
Free Cash Flow in the first quarter 2026 was $316 million, driven by net cash provided by operating activities, partially offset by capital expenditures, primarily related to continued enhancements and automation in the Company s distribution centers and investments in its kitting manufacturing facilities.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
EPSquarter
$ 129
$ 129 $ 322 $ (193) (59.9) % Earnings per share attributable to Medline Inc.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
Gross margin %quarter
25.0 %
Gross margin % 25.0 % 27.5 %
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
AI analysis
Q1 2026 · reported May 6, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q1 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Net income | 25.8% | — | — |
| Adjusted EPS | $0.16 | — | — |
| Free cash flow | $316 million | — | — |
| EPS | $ 129 | — | — |
| Gross margin % | 25.0 % | — | — |
Guidance · company-stated
Direction: Raised
“htm EX-99.1 Document May 6, 2026 Medline Reports First Quarter 2026 Results Net sales of $7.4 billion, an increase of 10.7% Net income of $239 million, a decrease of 25.8% Adjusted EBITDA 1 of $776 million, a decrease of 10.6% Raising full year 2026 Organic Sales 2 guidance range to 8.5% to 9.5% NORTHFIELD, Ill.”
“This performance gives us confidence to raise our full year Organic Sales guidance while continuing disciplined investments in our people, infrastructure and capabilities to support our strong customer demand and position Medline for sustained growth.”
“2026 Guidance The Company is increasing its full year 2026 outlook for Organic Sales 2 growth to 8.5% to 9.5%, comp ared to its previous outlook of 8% to 9% , and is maintaining its Adjusted EBITDA 2 outlook of $3.5 to $3.6 billion.”
Classified from the release's primary full-year outlook statement.
Margin
Cash flow & capex
Capital allocation
Free Cash Flow in the first quarter 2026 was $316 million, driven by net cash provided by operating activities, partially offset by capital expenditures, primarily related to continued enhancements and automation in the Company s distribution centers and investments in its kitting manufacturing facilities.
Event summary
First Quarter 2026 Results First quarter 2026 net sales increased 10.7% to $7.4 billion, compared to $6.6 billion in the first quarter 2025, with Organic Sales increasing 10.1%
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “htm EX-99.1 Document May 6, 2026 Medline Reports First Quarter 2026 Results Net sales of $7.4 billion, an increase of 10.7% Net income of $239 million, a decrease of 25.8% Adjusted EBITDA 1 of $776 million, a decrease of 10.6% Raising full year 2026 Organic Sales 2 guidance range to 8.5% to 9.5% NORTHFIELD, Ill.”
Revenue: “This performance gives us confidence to raise our full year Organic Sales guidance while continuing disciplined investments in our people, infrastructure and capabilities to support our strong customer demand and position Medline for sustained growth.”
Revenue: “2026 Guidance The Company is increasing its full year 2026 outlook for Organic Sales 2 growth to 8.5% to 9.5%, comp ared to its previous outlook of 8% to 9% , and is maintaining its Adjusted EBITDA 2 outlook of $3.5 to $3.6 billion.”
Revenue — Raised (“increase”)
“htm EX-99.1 Document May 6, 2026 Medline Reports First Quarter 2026 Results Net sales of $7.4 billion, an increase of 10.7% Net income of $239 million, a decrease of 25.8% Adjusted EBITDA 1 of $776 million, a decrease of 10.6% Raising full year 2026 Organic Sales 2 guidance range to 8.5% to 9.5% NORTHFIELD, Ill.”
Revenue — Raised (“raise”)
“This performance gives us confidence to raise our full year Organic Sales guidance while continuing disciplined investments in our people, infrastructure and capabilities to support our strong customer demand and position Medline for sustained growth.”
Revenue — Raised (“increasing”)
“2026 Guidance The Company is increasing its full year 2026 outlook for Organic Sales 2 growth to 8.5% to 9.5%, comp ared to its previous outlook of 8% to 9% , and is maintaining its Adjusted EBITDA 2 outlook of $3.5 to $3.6 billion.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Free Cash Flow in the first quarter 2026 was $316 million, driven by net cash provided by operating activities, partially offset by capital expenditures, primarily related to continued enhancements and automation in the Company s distribution centers and investments in its kitting manufacturing facilities.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
The Company believes Free Cash Flow and Net Leverage provide a measure of the Company s core operating performance, the cash-generating capabilities of the Company s business operations, and are factors used in determining the Company s borrowing capacity and the amount of cash available for debt repayments, acquisitions, and other corporate purposes.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
Free Cash Flow is defined as net cash provided by (used for) operating activities less net capital expenditures.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
The use of this non-GAAP measure does not imply or represent the residual cash flow for discretionary expenditures since the Company has certain non-discretionary obligations such as debt service that are not deducted from the measure.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
Net Leverage is defined as net debt (total debt less cash, cash equivalents and short-term investments) divided by Adjusted EBITDA.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
These forward-looking statements relate to matters such as our industry, business strategy, costs, and costs savings, impacts of accounting standards and guidance, goals and expectations, market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources, legal matters, trends, and other financial and operating information.
SEC original ↗Medline — 10-Q Quarterly report10-QAug 5, 2026
Strategy & priorities
Examples of forward-looking statements include, but are not limited to, statements related to the Company s industry, business strategy, costs, and cost savings, goals and expectations, market position, future operations, margins, profitability, annual guidance, and other financial and operating information.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
Factors that may cause actual results to differ from expected results include, but are not limited to inherent risks in the Company s global operations the Company s ability to derive fully the anticipated benefits from its existing or future acquisitions, joint ventures, investments, dispositions, or other strategic transactions consolidation in the healthcare industry competition and accelerating pricing pressure and changes in technology changes to the U.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
com, press releases, public conference calls and webcasts, and social media as routine channels of distribution to communicate important, and often material, information about Medline to investors and the public, including information about its financial performance and results, analyst and investor presentations, investor days, products, solutions, sustainability initiatives, and corporate governance practices.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
Management believes that presenting the Company s non-GAAP financial measures is useful to investors because it (i) provides investors with meaningful supplemental information regarding financial performance by excluding certain items that we do not consider indicative of our ongoing operating performance, (ii) permits investors to view performance using the same tools that management uses to budget, make operating and strategic decisions, and evaluate historical performance, and (iii) otherwise provides supplemental information that may be useful to investors in evaluating the Company s results.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
These forward-looking statements relate to matters such as our industry, business strategy, costs, and costs savings, impacts of accounting standards and guidance, goals and expectations, market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources, legal matters, trends, and other financial and operating information.
SEC original ↗Medline — 10-Q Quarterly report10-QAug 5, 2026
Risks & headwinds
First quarter 2026 net income decreased 25.8% to $239 million, compared to $322 million in the first quarter 2025, primarily driven by higher costs of goods sold including the impact of tariffs, higher operating expenses to support new customer growth and an employee bonus related to the Company s IPO.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
First quarter 2026 Adjusted EBITDA decreased 10.6% to $776 million, compared to $868 million in the first quarter 2025, primarily driven by higher costs of goods sold including the impact of tariffs and higher operating expenses to support new customer growth, partially offset by higher net sales.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
(2) Guidance for Adjusted EBITDA and Organic Sales is provided on a non-GAAP basis only because certain information necessary to calculate the most comparable GAAP measure is unavailable due to the uncertainty and inherent difficulty of predicting the occurrence and the future financial statement impact of such items impacting comparability, including, but not limited to, inventory-related adjustments, stock-based compensation, litigation (gains) charges, net, transaction-related costs, the impact of currency, and other non-core (gains) charges, among other items.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
Therefore, as a result of the uncertainty and variability of the nature and amount of future adjustments, which could be significant, the Company is unable to provide a reconciliation of these measures with reasonable certainty and without unreasonable effort.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
The forward-looking statements are based on management s current expectations and are subject to various risks, uncertainties, and changes in circumstances, many of which are beyond the Company s control, that could cause actual results to differ materially.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
Adjusted EBITDA is defined as net income (loss) adjusted for (i) interest expense, net, (ii) provision for income taxes, (iii) depreciation and amortization, (iv) inventory-related adjustments, (v) stock-based compensation, (vi) litigation (gains) charges, net, (vii) transaction-related costs, and (viii) other non-core (gains) charges.
SEC original ↗Medline — Earnings release (8-K exhibit)EX-99May 6, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
12 documentsEarnings releases
3 documentsPresentations
0 documentsNo presentations for Medline are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Medline are held in this edition of the library.
Mentioned by
4 companiesOther tracked companies whose held documents mention Medline by name or ticker. A mention is counted once per document, from the document text the library holds.
“rk … … (273) (82.0) % $ 189 $ 655 $ (466) (71.1) % Earnings per share attributable to Medline Inc. Basic $ 0.07 N/A $ 0.23 N/A Diluted $ 0.07 N/A $ 0.23 N/A Weighted-average number of Class A common… …$920 million, driven by net cash prov”
W. R. Berkley Corporation (WRB)
“sion-making and machine learning technologies and the evolving regulatory framework … …to Medline Inc. $ 129 $ 322 $ (193) (59.9) % Earnings per share attributable to Medline Inc. Basic $ 0.16 N/A Diluted $ 0.16 N/A Weighted-average numbe”
“ audits… … $ 182 NM (2) $ 1,159 $ — $ 1,159 NM (2) Net loss per share attributable to Medline Inc. (1) Basic and diluted $ (0.01) N/A $ (0.01) N/A Weighted average number of Class A common shares outstanding… … of 2025 was $1.3 billion, pri”
“vities $649 million; free cash flow increased to $448 million, +$423 million versus… … to Medline for $950 million in cash. OUTLOOK ● 2024: Increased full year 2024 adjusted diluted earnings per share range to $6.40 - $6.70, +23% - 29%, from prio”
See also the earnings calendar for every tracked company’s next earnings date.